The purpose of this study is to determine how effective and safe the immune drug Nivolumab is for patients who have newly diagnosed cutaneous melanoma. Nivolumab is an anti-body, a type of human protein, that is being tested to see if it will allow the body's immune system to work against tumor cells. If you are eligible for the study, you will…
We are conducting a CoVPN-funded study to understand if monoclonal antibodies can protect people exposed to SARS-COV-2 from developing the COVID-19 disease that it causes. If you live with someone recently diagnosed with COVID, you may be eligible to participate in one or more study visits. At each visit you will be asked to provide blood, nasal, and urine…
The HERO program has two parts: the HERO Registry and the HERO-HCQ Trial. The HERO Registry is asking hundreds of thousands of U.S. healthcare professionals to join, including nurses, therapists, physicians, emergency responders, food service workers, environmental services workers, interpreters, and transporters anyone who…